Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.55 USD
0.00 (0.17%)
Updated Sep 23, 2024 10:26 AM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MIST 1.55 0.00(0.17%)
Will MIST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MIST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIST
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know
Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround
MIST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why
Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks
Other News for MIST
Milestone partner announces Phase 3 study of etripamil met primary endpoint
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
Milestone Pharmaceuticals Welcomes New Directors and Auditor
Milestone Pharmaceuticals appoints Joseph Papa to board of directors